Elfabrio (pegunigalsidase alfa)
- Region
- 🇪🇺 EU
- Active substance
- pegunigalsidase alfa
- Company
- Chiesi Farmaceutici S.p.A
- Status
- Authorised
- Therapeutic area
- Fabry Disease
- CHMP opinion
- Thu 23 Feb 2023
- EU approval
- Thu 04 May 2023
- Application
- EMEA/H/C/005618
- ATC
- A16AB20
- Official record
- www.ema.europa.eu
Indication
Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
Regulatory milestones
No milestones recorded in the last year.
Follow Elfabrio
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.